| Diabetes | Insulin Resistance | Obesity | Hypertension | Autonomic nervous system activation | Non ischemic cardiomyopathy | Endothelium dysfunction | Mortality rate evaluation | Main limitations | |
| HUMAN | ++ | ++ | ++ | ++ | ++ | ++ | ++ | ++ | Reference |
| db/db and ob/ob mice | ++ | ++ | ++ | - | - | +/- | + | - | Leptin or leptin receptor mutation |
| ZDF | ++ | ++ | ++ | - | - | +/- | + | - | Leptin or leptin receptor mutation |
| Zucker fafa | - | ++ | ++ | - | - | +/- | + | - | Leptin receptor mutation |
| Streotozotocin rat/mouse | ++ | - | - | - | - | +/- | ? | - | Hypoinsulinemia model of Type 1 diabetes |
| DIO rat/mouse | - | + | + | - | - | - | - | - | No clear cardiovascular dysfunction |
| SHR rat | - | + | - | ++ | ++ | + | ++ | - | Absence of metabolic features |
| SD rat + PGX1 diet | Borderline | + | ++ | + | + | + | + | - | Focused on vascular/cardiac impairments due to insulin resistance and lipotoxicity exept atherosclerosis |
| Dahl rat + PGX2 Diet | Borderline | + | + | ++ | ++ | ++ | ++ | + | Focused on vascular/cardiac impairments due to insulin resistance and lipotoxicity exept atherosclerosis |
